ArticleNPJ precision oncology2026

Genomic co-alterations and immune-related adverse events shape outcomes of thymic malignancies treated with immune checkpoint inhibitors.

Harold Nathan Tan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.